Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The balance between thrombosis and hemostasis is a difficult issue during extracorporeal membrane oxygenation (ECMO) support. The pathogenesis leading to thrombotic complications during ECMO support is not well understood. Neutrophil extracellular traps (NETs) were reported to participate in thrombosis and have a key role in inflammation. This study aimed to explore the role of NETs in thrombosis during ECMO support and investigate NETs as a predictive biomarker for thrombotic complications during ECMO assistance.
Methods: Ten ovine models of ECMO support were established. Animals were then randomly divided into 2 groups (5 sheep/group): venoarterial (VA) ECMO group and venovenous (VV) ECMO group. The venous blood samples were collected at different time points. Markers of NETs were detected in plasma, neutrophils, and thrombi from the vessels and membrane. Moreover, circulating NETs levels in 8 adults treated in the intensive care unit (ICU) who received VA-ECMO and 8 healthy controls were detected; patient survival was also recorded.
Results: In vivo study showed that neutrophils and NETs markers (dsDNA and citH3) levels were significantly elevated 6 h after ECMO compared to baseline. Isolated neutrophils from fresh blood at 6 h could release more NETs. dsDNA and citH3 levels were significantly higher in the VA mode than in the VV mode. NETs were found in thrombi from the vessel and membrane. Clinical data further revealed that dsDNA, citH3, and nucleosomes were higher in patients who received ECMO than in healthy controls.
Conclusions: These data suggest NETs might be associated with thrombus during ECMO support, especially in the VA mode. These findings provide new insight into preventing thrombotic complications by targeting NETs. Also, NETs may potentially become an early warning biomarker for thrombosis under ECMO assistance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.thromres.2022.10.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Left ventricular unloading in patients with cardiogenic shock treated with veno-arterial extracorporeal membrane oxygenation.
Eur Heart J Open
September 2025
Calderdale and Huddersfield NHS Foundation Trust, Acre St, Lindley, Huddersfield HD3 3EA, UK.
Aims: Cardiogenic shock remains a significant cause of mortality despite multiple advancements in medical interventions. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) provides crucial circulatory support but also increases left ventricular (LV) after-load, potentially worsening outcomes. Effective LV unloading strategies can enhance patient survival during VA-ECMO treatment.
View Article and Find Full Text PDFHarlequin Syndrome in Venoarterial ECMO and ECPELLA: When ECMO and Native or Impella Circulations Collide - A Comprehensive Review.
Rev Cardiovasc Med
August 2025
Department of Neurosciences, Institute of Human Anatomy, University of Padova, 35121 Padova, Italy.
Harlequin syndrome, also known as differential hypoxia (DH) or North-South syndrome, is a serious complication of femoro-femoral venoarterial extracorporeal membrane oxygenation (V-A ECMO). Moreover, Harlequin syndrome is caused by competing flows between the retrograde oxygenated ECMO output and the anterograde ejection of poorly oxygenated blood from the native heart. In the setting of impaired pulmonary gas exchange, the addition of an Impella device (ECPELLA configuration), although beneficial for ventricular unloading and hemodynamic support, may further exacerbate this competition and precipitate DH.
View Article and Find Full Text PDFAnalysis of United Network for Organ Sharing: Neurodevelopmental Outcomes of Mechanical Circulatory Support as a Bridge-to-Transplantation in Pediatric Heart Transplant Recipients.
World J Pediatr Congenit Heart Surg
September 2025
Congenital Heart Center, Departments of Surgery and Pediatrics, University of Florida, Gainesville, FL, USA.
This analysis evaluates the longitudinal impact of extracorporeal membrane oxygenation (ECMO) and ventricular assist device (VAD) on the progression of motor delay and cognitive delay in pediatric heart transplant recipients. The United Network for Organ Sharing Registry was queried for pediatric patients (<18 years) who received a heart transplant between 2008 and 2022 and were bridged-to-transplantation with either ECMO or VAD. Patients were further stratified based on the progression of delay status pretransplant to post-transplant.
View Article and Find Full Text PDFAeromedical Transport With Combined Extracorporeal Circulatory and Renal Support Bridging a Critically Ill Patient to Heart Transplantation.
ASAIO J
September 2025
From Airlec Medical, Mérignac, France.
Long-distance aeromedical transport of critically ill patients is an increasingly important component of modern intensive care. However, the combination of veno-arterial extracorporeal membrane oxygenation (VA ECMO) and renal replacement therapy (RRT) during an intercontinental flight had never been previously documented. This case report describes the first known case of a 27 year old patient with fulminant viral myocarditis and multi-organ failure who was successfully repatriated from Bangkok (Thailand) to Paris (France) while receiving both VA ECMO and 6 hours of in-flight sustained low-efficiency dialysis (SLED).
View Article and Find Full Text PDFOutcomes of a Second Run of Extracorporeal Membrane Oxygenation in Neonates: A Propensity Score Matched Analysis of a Nationwide Registry.
ASAIO J
September 2025
Section of Pediatric Surgery, Department of Surgery, Aga Khan University, Pakistan.
This study analyzed the outcomes of neonates undergoing a second run of extracorporeal membrane oxygenation (ECMO) to determine whether there is a benefit to a repeated run. We used Extracorporeal Life Support Organization data to compare neonates undergoing a single versus two runs of ECMO from 2009 to 2019. Baseline characteristics of single-run patients were compared with the first run in two-run patients to identify clinical predictors of a second run of ECMO.
View Article and Find Full Text PDF